DESCRIBE <http://purl.uniprot.org/citations/28090669>

Subject	Predicate	Object
http://purl.uniprot.org/citations/28090669	http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/28090669	http://www.w3.org/2000/01/rdf-schema#comment	" Objective To determine whether sclerostin is associated with fasting glucose, insulin levels, insulin resistance or increased risk of incident type 2 diabetes. Background Type 2 diabetic patients have a higher risk of fractures. Recent studies suggest sclerostin, a regulator of osteoblast activity, is associated with diabetes. Materials and methods Sclerostin levels were obtained from 1778 individuals with no history of type 2 diabetes participating in the population-based Canadian Multicentre Osteoporosis Study (CaMos) cohort. Participants were followed until diagnosis of type 2 diabetes, death or end of the study period (31 December 2013). The relationship of sclerostin with fasting glucose, insulin levels and homoeostatic model assessment-insulin resistance (HOMA-IR) was studied in linear regression models. Cox proportional hazards models were used to determine the association of sclerostin levels and the risk of incident type 2 diabetes during a mean 7·5 years of follow-up. Results Fasting glucose, fasting insulin levels and HOMA-IR were weakly correlated with sclerostin levels (Spearman's correlation coefficient: 0·11, P < 0·05; -0·09, P < 0·05; and -0·07, P = 0·02, respectively). Multiple linear regression analyses confirmed a significant association between sclerostin and fasting insulin and HOMA-IR but no significant association with fasting glucose levels. Sclerostin levels were not found to be significantly associated with the risk of incident type 2 diabetes (HR: 1·30; 95% CI: 0·37-4·57). Conclusions We observed an association between sclerostin levels with fasting insulin levels and HOMA-IR, but there was no clear association with type 2 diabetes risk. Further studies are needed to understand the role of sclerostin in type 2 diabetes."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.org/dc/terms/identifier	"doi:10.1111/cen.13300"xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Berger C."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Josse R.G."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Goltzman D."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Richards B."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Kaiser S.M."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Kovacs C.S."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Yu O.H."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Davison K.S."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/author	"Leslie W.D."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/date	"2017"xsd:gYear
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/name	"Clin Endocrinol (Oxf)"xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/pages	"520-525"xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/title	"The association between sclerostin and incident type 2 diabetes risk: a cohort study."xsd:string
http://purl.uniprot.org/citations/28090669	http://purl.uniprot.org/core/volume	"86"xsd:string
http://purl.uniprot.org/citations/28090669	http://www.w3.org/2004/02/skos/core#exactMatch	http://purl.uniprot.org/pubmed/28090669
http://purl.uniprot.org/citations/28090669	http://xmlns.com/foaf/0.1/primaryTopicOf	https://pubmed.ncbi.nlm.nih.gov/28090669
http://purl.uniprot.org/uniprot/#_Q7Z2R3-mappedCitation-28090669	http://www.w3.org/1999/02/22-rdf-syntax-ns#object	http://purl.uniprot.org/citations/28090669
http://purl.uniprot.org/uniprot/#_Q7Z4G0-mappedCitation-28090669	http://www.w3.org/1999/02/22-rdf-syntax-ns#object	http://purl.uniprot.org/citations/28090669
http://purl.uniprot.org/uniprot/#_Q9BQB4-mappedCitation-28090669	http://www.w3.org/1999/02/22-rdf-syntax-ns#object	http://purl.uniprot.org/citations/28090669
http://purl.uniprot.org/uniprot/Q7Z2R3	http://purl.uniprot.org/core/mappedCitation	http://purl.uniprot.org/citations/28090669
http://purl.uniprot.org/uniprot/Q7Z4G0	http://purl.uniprot.org/core/mappedCitation	http://purl.uniprot.org/citations/28090669
http://purl.uniprot.org/uniprot/Q9BQB4	http://purl.uniprot.org/core/mappedCitation	http://purl.uniprot.org/citations/28090669